Table 2.
Treatment characteristics of patients with DKA grouped by COVID-19 status
| Baseline characteristic | COVID(−) DKA (n = 93) | COVID(+) DKA (n = 15) |
|---|---|---|
| Length of stay, days | 0.9 (0.8–1.2) | 1.2 (0.8–1.5) |
| Mean insulin infusion rate, units/kg/min* | 1.7 (1.7–1.7) | 1.7 (1.7–1.7) |
| Total intravenous insulin infused, units/kg | 1.32 (1.00–1.84) | 1.56 (1.07–2.25) |
| Total insulin infusion time, h | 13.3 (10.0–18.7) | 15.6 (10.7–23.0) |
| Mean GIR, mg/kg/min† | 3.8 (3.0–4.5) | 3.3 (2.8–3.4) |
| Total dextrose infused, g/kg | 2.5 (1.8–3.5) | 2.9 (1.3–4.3) |
| Final plasma glucose, mg/dL‡ | 118 (89–146.5) | 112 (88–183) |
| Final BUN, mg/dL‡ | 10 (9–14) | 11 (8–16) |
| Final creatinine, mg/dL‡ | 0.89 (0.77–1.04) | 1.01 (0.85–1.13) |
| Final BUN-to-creatinine ratio‡ | 11.8 (9.5–14.9) | 12.9 (8.3–14.6) |
| Final eGFR (mL/min/m2)‡ | 72.4 (62.9–83.2) | 66.9 (60.2–77.7) |
Data are summarized as median (interquartile range). Estimated glomerular filtration rate (eGFR) calculated with bedside Schwartz equation. BUN, blood urea nitrogen.
*
From start to completion of intravenous insulin infusion.
†
From start of glucose infusion until end of insulin infusion.
‡
Immediately preceding discontinuation of the intravenous insulin infusion.